1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Research on China’s FISH Probe (Fluorescent in Situ Hybridization Probe) Industry, 2013-2017

According to Huidian’s market research, the output value of China’s FISH probe market in 2012 was about CNY 20 million to CNY 30 million; with the improvement of people’s living standard and medical conditions in the future, FISH probe products will be more and more used in medical diagnosis.

The main brands of China’s FISH probe industry are GP, Abbott, LBP, Zhongsheng Damaidi, BioChina and Zhejiang Orient Gene. In 2012, the FISH probes of GP and Abbott occupied the monopoly position in domestic market, and the market share was about 51% and 32 % respectively, and the market share of LBP was about 13%.

At present, the annual sales of China’s clinical diagnostic reagent market has developed to CNY 3 billion to CNY 4 billion, of which, clinical biochemistry accounted for 30%, the immune products accounted for 25%, and the blood products and urine analysis products ranged from 8% to 10% and 3% to 5% respectively, the microbial products accounted for 2% to 3%. According to the estimate of experts, the annual growth rate of domestic clinical diagnostic market will reach 15% to 20% in the next five years.

Huidian Research predicts that the growth rate of FISH probe market will be not lower than 15% in the future. Therefore, it is estimated that the output value in this market will be about CNY 32 million in 2013, and this number will reach CNY 56 million by 2017.

Table Of Contents

Research on China’s FISH Probe (Fluorescent in Situ Hybridization Probe) Industry, 2013-2017
1. Overview of China's FISH Probe Products
1.1 Product Overview
1.1.1 Introduction
1.1.2 Classification
1.1.3 Advantages
1.2 FISH Technology and Similarities and Differences Compares With Other Technologies
1.3 Application Areas

2. Development Environment of China's FISH Probe Industry
2.1 Economic Environment
2.1.1 Development of Macro-economy
2.1.2 Income Growth
2.1.3 Investment in the Fixed Assets
2.1.4 Changes of RMB Exchange Rate
2.2 Policy Environment
2.3 Social Environment
2.3.1 Population Size
2.3.2 Age Structure
2.3.3 Sex Structure

3. Development of Global FISH Probe Industry

4. Status Quo of China's FISH Probe Industry
4.1 Status Quo
4.2 Competitive Structure
4.3 Development Cycle

5. Economic Operation of China's FISH Probe Industry, 2009 - June, 2012
5.1 Production and Sales
5.2 Scale
5.3 Profitability
5.4 Operation and Development Ability
5.5 Debt Paying Ability

6. Analysis and Forecast of Market Demand and Supply in China's FISH Probe Industry
6.1 Supply Analysis and Forecast
6.2 Product Applications
6.2.1 Application in Antenatal and Abortion Diagnosis
6.2.2 Application in Breast Cancer
6.2.3 Application in Bladder Cancer
6.2.4 Application in Cervical Cancer
6.2.5 Application in Lung Cancer
6.2.6 Application Blood Disease
6.2.7 Application in Other Tumors
6.3 Demand Analysis and Forecast

7. Technology Development of China's FISH Probe Industry
7.1 Technology Development History
7.1.1 Development of FISH Technical Detection Locus Number and Detection Target
7.1.2 Quantitative Analysis Phase
7.1.3 Development of Detection Field
7.2 Existing Problems of FISH Technology

8. Key Enterprises in China's FISH Probe Industry
8.1 Abbott
8.1.1 Company Profile
8.1.2 Products Introduction
8.1.3 Main Clients
8.1.4 State of Operation
8.2 LBP Pharmaceutical Science and Technology Co., Ltd.
8.2.1 Company Profile
8.2.2 Main Clients
8.2.3 Scientific Research Strength
8.2.4 Production Capacity
8.2.5 State of Operation
8.3 BioChina Group
8.3.1 Company Profile
8.3.2 Main Clients
8.3.3 State of Operation
8.4 Beijing Zhongsheng Damaidi Molecular Diagnosis Technology Co., Ltd. (A Subsidiary of BioSino Bio-technology and Science Inc.)
8.4.1 Company Profile
8.4.2 Main Clients
8.4.3 State of Operation
8.5 Zhejiang Orient Gene Biotech Co., Ltd.
8.5.1 Company Profile
8.5.2 Introduction of Main Products
8.5.3 State of Operation

9. Challenges and Opportunities of China's FISH Probe Industry
9.1 Challenges
9.1.1 Policy Challenge
9.1.2 Market Challenge
9.1.3 Technology Challenge
9.1.4 Management Challenge
9.2 Development Opportunity

10. Development and Strategy Analysis of China's FISH Probe Industry
10.1 Development Trend
10.2 Development Direction
10.3 Strategy
10.3.1 Marketing Strategy
10.3.2 Scientific Research Strategy
10.3.3 Operating Strategy




Companies Mentioned

Abbott
LBP Pharmaceutical Science and Technology Co., Ltd.
BioChina Group
Beijing Zhongsheng Damaidi Molecular Diagnosis Technology Co., Ltd. (A Subsidiary of BioSino Bio-technology and Science Inc.)
Zhejiang Orient Gene Biotech Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.